(Q38171683)

30 August 2017

title

Systemic lupus erythematosus in 2013. Taking a closer look at biologic therapy for SLE. (English)

1 reference

systemic lupus erythematosus

30 August 2017

main subject

1 reference

1 reference

1

David A Isenberg

1 reference

30 August 2017

Anisur Rahman

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

17 December 2013

1 reference

Nature Reviews Rheumatology

30 August 2017

published in

1 reference

30 August 2017

volume

10

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

71-72

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2013.203

30 August 2017

exact match

0 references

cites work

Damage in lupus patients--what have we learned so far?

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.203

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.203

Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.203

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.203

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.203

Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.203

Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.203

Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.203

Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.203

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.203

31 March 2020

Identifiers

DOI

10.1038/NRRHEUM.2013.203

1 reference

Dimensions Publication ID

30 August 2017

1002738034

0 references

1 reference